Impact of a Whey Protein Hydrolysate Treated by Electrodialysis with Ultrafiltration Membrane on the Development of Metabolic Syndrome and the Modulation of Gut Microbiota in Mice

Int J Mol Sci. 2023 Aug 19;24(16):12968. doi: 10.3390/ijms241612968.

Abstract

The development of Metabolic Syndrome (MetS) affects a large number of people around the world and represents a major issue in the field of health. Thus, it is important to implement new strategies to reduce its prevalence, and various approaches are currently under development. Recently, an eco-friendly technology named electrodialysis with ultrafiltration membrane (EDUF) was used successfully for the first time at a semi-industrial scale to produce three fractions concentrated in bioactive peptides (BPs) from an enzymatically hydrolyzed whey protein concentrate (WPC): the initial (F1), the final (F2) and the recovery fraction (F3), and it was demonstrated in vitro that F3 exhibited interesting DPP-IV inhibitory effects. Therefore, the present study aimed to evaluate the effect of each fraction on in vivo models of obesity. A daily dose of 312.5 mg/kg was administered to High Fat/High Sucrose diet (HFHS) induced C57BL6/J mice for eight weeks. The physiological parameters of each group and alterations of their gut microbiota by the fractions were assessed. Little effect of the different fractions was demonstrated on the physiological state of the mice, probably due to the digestion process of the BP content. However, there were changes in the gut microbiota composition and functions of mice treated with F3.

Keywords: bioactive peptides; digestion; electrodialysis with ultrafiltration membrane; electromembrane extraction; gut microbiota; whey protein hydrolysate.

MeSH terms

  • Animals
  • Gastrointestinal Microbiome*
  • Metabolic Syndrome* / therapy
  • Mice
  • Mice, Inbred C57BL
  • Protein Hydrolysates / pharmacology
  • Ultrafiltration
  • Whey

Substances

  • Protein Hydrolysates